Table 1. Demographic and clinical characteristics of home-based and center-based groups.
| Home-based (n=11) | Center-based (n=12) | p-value | |
|---|---|---|---|
| Age, mean±SD (years) | 59±5 | 61±7 | 0.733 |
| Male, n (%) | 5 (46) | 9 (75) | 0.147 |
| BMI, mean±SD (kg/m2) | 28±4 | 27±3 | 0.460 |
| LVEF, mean±SD (%) | 31±6 | 32±6 | 0.711 |
| NYHA II, n (%) | 10 (91) | 11 (92) | 0.949 |
| Duration of HF, mean±SD (years) | 11±8 | 9±9 | 0.557 |
| Etiology, n (%) | 0.278 | ||
| Ischemic | 2 (18) | 6 (50) | 0.265 |
| Dilated | 6 (55) | 4 (33) | 0.265 |
| Cardiac rhythm, n (%) | 0.339 | ||
| Sinus rhythm | 8 (73) | 8 (67) | 0.752 |
| Atrial fibrillation | 0 (0) | 2 (17) | 0.156 |
| Implantable cardiac device | 3 (27) | 2 (17) | 0.538 |
| Other morbidities, n (%) | |||
| Hypertension | 10 (91) | 10 (83) | 0.590 |
| Diabetes | 3 (27) | 3 (25) | 0.901 |
| Dyslipidemia | 8 (73) | 7 (58) | 0.469 |
| Myocardial infarction | 4 (36) | 6 (50) | 0.510 |
| Smoking status | 0.265 | ||
| Never smoker, n (%) | 2 (18) | 6 (50) | 0.110 |
| Ex-smoker, n (%) | 8 (73) | 5 (42) | 0.133 |
| Current smoker, n (%) | 1 (9) | 1 (8) | 0.949 |
| Mean pack-years | 15±16 | 11±17 | 0.187 |
| Medications, n (%) | |||
| Amiodarone | 4 (36) | 4 (33) | 0.879 |
| Diuretics | 10 (91) | 9 (75) | 0.315 |
| Spironolactone | 6 (55) | 7 (58) | 0.855 |
| Beta blockers | 11 (100) | 12 (100) | 0.999 |
| Angiotensin-converting enzyme inhibitors | 7 (64) | 9 (65) | 0.554 |
| Angiotensin II receptor blockers | 3 (27) | 1 (8) | 0.231 |
| Digoxin | 1 (9) | 0 (0) | 0.286 |
| Anticoagulants | 1 (9) | 1 (8) | 0.949 |
| Antiplatelets | 8 (73) | 9 (75) | 0.901 |
| Statins | 6 (55) | 10 (83) | 0.134 |
Continuous data: Mann-Whitney test; categorical data: chi-squared test BMI, body mass index; HF, heart failure; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association functional classification.